In a Phase 2 study, researchers found that rontalizumab was a more effective treatment in patients with systemic lupus erythematosus who had an interferon signature metric score lower than 1.
Patients with systemic lupus erythematosus (SLE) are characterized by high-titer, highly specific, isotype-switched antibodies against DNA and RNA. Patients have both CD4+ T helper (Th) cell- dependent as well as Th cell-independent autoantibody production. Two mouse models of lupus demonstrate T-cell–independent autoantibody production: the pristane model of lupus, as well as in the MRL/lpr mouse…
In 1984, I wrote my first prescription for the antimalarial drug, hydroxychloroquine (Plaquenil), for a 28-year-old woman with SLE. She was considerably overweight, with inflammatory arthritis and a photosensitive rash, and I worried that oral corticosteroids would tip her over into diabetes. I presented the case to my attending, Steven Malawista, MD, at the Yale…